Methocarbamol

Evidence Level: L5

Predicted Indications: 10

Methocarbamol

Pharmacist Assessment Report

Methocarbamol: From Muscle Spasm (Musculoskeletal Conditions) to Cauda Equina Syndrome

One-Sentence Summary

Methocarbamol is a centrally acting skeletal muscle relaxant that is marketed in India as tablets and an injection. The TxGNN model predicts it may be effective for Cauda Equina Syndrome, but no clinical trials and no publications support this prediction. It is a computational prediction only, so the evidence is very weak.

Quick Overview

Item	Content
Original Indication	Not stated in the India license data (methocarbamol is generally used as a muscle relaxant for painful muscle spasm)
Predicted New Indication	Cauda equina syndrome
TxGNN Prediction Score	0.9998
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data
Number of Listed Products	3 (valid: 3)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, methocarbamol is a centrally acting skeletal muscle relaxant. A plausible link would be symptomatic relief of muscle spasm or pain associated with the condition.

Cauda equina syndrome is caused by compression of the nerve roots at the base of the spinal cord, and it is a surgical emergency. Methocarbamol would not treat the underlying compression. At most, it could play a supportive, symptomatic role. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.

Other top-ranked predictions are also unsupported by the data compiled for this report. These are irritable bowel syndrome, panuveitis, anaphylaxis, iris disease, uveitis, ventricular tachycardia, food-dependent exercise-induced anaphylaxis, conjunctivitis and obsolete bundle branch block. For these, no plausible mechanistic link could be drawn. The only literature retrieved was for anaphylaxis and ventricular tachycardia, and it does not show efficacy (see below).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for cauda equina syndrome.

For the lower-ranked predictions, the following papers were retrieved. They do not show therapeutic benefit:

PMID	Year	Type	Journal	Key Findings
20086833	1998	Review	The Physician and Sportsmedicine	General review of arthropod bites and stings. Methocarbamol is mentioned only as an option for symptoms after widow spider bites. It is not an anaphylaxis treatment (anaphylaxis prediction, rank 4).
42543011	2026	Review	Orvosi Hetilap	Compares side-effect profiles of centrally acting muscle relaxants. It concerns safety, not benefit, and notes anaphylactic reactions with tolperisone (anaphylaxis prediction, rank 4).
30050852	2017	Case report (veterinary)	Veterinary Medicine (Auckland)	Severe lamotrigine toxicosis in a dog. It is not about methocarbamol efficacy and gives no evidence for ventricular tachycardia (rank 7).

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
136699	Mecotha Tablet	Strip of 10 tablets	Not stated
184792	Robinax 100mg Injection	Vial of 10 ml injection	Not stated
184528	Robinax 500mg Tablet	Strip of 10 tablets	Not stated

All three licenses are valid single-ingredient products. There are no combination products and no cancelled licenses.

Safety Considerations

Contraindications suggested by the knowledge graph (not label text): The TxGNN knowledge graph links methocarbamol with contraindications in these conditions: epilepsy, kidney disease, liver disease, gallbladder disease, thrombocytopenia and thrombocytopenic purpura, peptic ulcer disease (including active disease) and gastritis, gout, substance abuse/dependence, anaemia (including macrocytic anaemia), bleeding disorders (haemophilia, von Willebrand disease, congenital prothrombin deficiency, vitamin K deficiency haemorrhagic disease), Reye syndrome, Alzheimer disease, Pick disease, cerebellar degeneration, nasal cavity polyp and pyoureter. These should be verified against the official package insert.
Drug Interactions: 126 interactions were recorded. The main ones are:
- Major: morphine and liposomal morphine (additive central nervous system and respiratory depression is the expected concern).
- Moderate: dronabinol, nabilone, metoclopramide, opium and sibutramine.
- Further interactions with unknown severity were recorded, including metformin, glimepiride, omeprazole, pantoprazole and doxycycline.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests only on a TxGNN computational score, with no clinical trials or supporting literature. Methocarbamol cannot treat the underlying nerve compression in cauda equina syndrome, and the best case is symptomatic relief.

To proceed, the following is needed:

Package insert warnings, contraindications and approved indications from the India license documents
Mechanism of action data (for example from DrugBank)
Clinical or observational evidence for the predicted indication, or a reasoned choice of a more plausible candidate indication
Review of the knowledge graph contraindication signals, especially for hepatic, renal and haematological conditions
A route-of-administration compatibility assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.